ArticleNature communications2025
Anti-swelling and self-activating artificial proteoglycan assemblies as cartilaginous implant for post-microfracture healing.
Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
The poor structural stability and insufficient endogenous activation of cartilaginous implant might be key factors for cartilage regeneration after microfracture. Herein, inspired by the restrictive effect of collagen fibers on proteoglycans, we develop artificial proteoglycan assemblies (DSPG@Pep) through sequential co-assembly of bioactive polysaccharide, protein and peptides via electrostatic interactions and covalent conjugation. The DSPG@Pep presents anti-swelling, compression and degradation resistance properties, and significantly activates endogenous stem cell recruitment and direct chondrogenic differentiation. Specifically, the DSPG@Pep downregulates the calcium signaling pathway (e.g., CACNA1G, AVPR1A, et al.) and ECM-receptor interaction (IBSP and COL4A2), thus reduces ossification (EFEMP1, SCUBE3, and SPARCL1) tendency as evidenced by decreased cytosolic calcium concentration and integrin β1 clustering. Cartilage defects models in male rabbits and pigs confirm the DSPG@Pep can be stably immobilized in the defect sites and facilitate the structural and functional remodeling of neocartilage. These findings provide a promising biomaterial design strategy for endogenous cartilage regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.